1 |
Camilleri M. Guanylate cyclase C agonists: emerging gastrointestinal therapies and actions[J]. Gastroenterology, 2015, 148(3): 483-487.
|
2 |
Heidelbaugh JJ, Stelwagon M, Miller SA, et al.The spectrum of constipation-predominant irritable bowel syndrome and chronic idiopathic constipation: US survey assessing symptoms, care seeking, and disease burden[J]. Am J Gastroenterol, 2015, 110(4): 580-587.
|
3 |
Molodecky NA, Soon IS, Rabi DM, et al.Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review[J]. Gastroenterology, 2012, 142(1): 46-54.
|
4 |
Shailubhai K, Comiskey S, Foss JA, et al.Plecanatide, an oral guanylate cyclase C agonist acting locally in the gastrointestinal tract, is safe and well-tolerated in single doses[J]. Dig Dis Sci, 2013, 58(9): 2580-2586.
|
5 |
Agostini A, Ballotta D, Righi S, et al.Stress and brain functional changes in patients with Crohn′s disease: A functional magnetic resonance imaging study[J]. Neurogastroenterol Motil, 2017, 29(10): 1-10.
|
6 |
van Oijen MG, Josemanders DF, Laheij RJ, et al.Gastrointestinal disorders and symptoms: does body mass index matter?[J]. Neth J Med, 2006, 64(2): 45-49.
|
7 |
Sadik R, Björnsson E, Simrén M. The relationship between symptoms, body mass index, gastrointestinal transit and stool frequency in patients with irritable bowel syndrome [J]. Eur J Gastroenterol Hepatol, 2010, 22(1): 102-108.
|
8 |
Compare D, Coccoli P, Rocca A, et al.Gut-liver axis: the impact of gut microbiota on non alcoholic fatty liver disease [J]. Nur Metab Cardiovasc Dis, 2012, 22(6): 471-476.
|
9 |
中华人民共和国卫生部疾病预防控制司.中国成人超重和肥胖症预防控制指南[M].北京:人民卫生出版社,2006:1-36.
|
10 |
Fang YJ, Liou JM, Chen CC, et al.Distinct aetiopathogenesis in subgrou ps of functional dyspepsia according to the Rome III criteria[J]. Gut 2015, 64(10): 1517-1528.
|
11 |
Mukhtar K, Nawaz H. Functional gastrointestinal disorders and gut-brain axis: What does the future hold?[J]. World J Gastroenterol, 2019, 25(5): 552-566.
|
12 |
Jones MP, Tack J, Van Oudenhove L, et al.Mood and Anxiety Disorders Precede Development of Functional Gastrointestinal Disorders in Patients but Not in the Population[J]. Clin Gastroenterol Hepatol, 2017, 15(7): 1014-1020.
|
13 |
Saffouri GB, Shields-Cutler RR, Chen J, et al.Small intestinal microbial dysbiosis underlies symptoms associated with functional gastrointestinal disorders[J]. Nature communications, 2019, 10(1): 2012.
|
14 |
Piche T. Tight junctions and IBS-the link between epithelial permeability, low-grade inflammation, and symptom generation[J]. Neurogastroenterol Motil, 2014, 26(3): 296.
|
15 |
Fritscherravens A, Schuppan D, Ellrichmann M, et al.Confocal endomicroscopy shows food-associated changes in the intestinal mucosa of patients with irritable bowel syndrome[J]. Gastroenterology, 2014, 147(5): 1012.
|
16 |
Farmer AD, Aziz Q. Gut pain&visceral hypersensitivity[J]. Br J Pain, 2013, 7(1): 39-47.
|
17 |
Cozma-Petruţ A, Loghin F, Miere D. Diet in irritable bowel syndrome: What to recommend, not what to forbid to patients![J]. World J Gastroenterol, 2017, 23(21): 3771-3783.
|
18 |
Camilleri M. Dietary and pharmacological treatment of abdominal pain in IBS[J]. Gut, 2017, 66(5): 966-974.
|
19 |
Camilleri M. Management Options for Irritable Bowel Syndrome[J]. Mayo Clinic Proceedings, 2018, 93(12): 1858-1872.
|
20 |
Weaver KR, Melkus GD, Henderson WA.Irritable Bowel Syndrome[J]. Am J Nurs, 2017, 117(6): 48-55.
|
21 |
Varghese MJ, Sharma G, Shukla G, et al.Longitudinal ventricular systolic dysfunction in patients with very severe obstructive sleep apnea: A case control study using speckle tracking imaging[J]. Indian Heart J, 2017, 69(3): 305-310.
|
22 |
Cesare MD, Bentham J, Stevens GA, et al.Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population based measurement studies with 19.2 million participants[J]. Lancet, 2016, 387(10026): 1377-1396.
|